Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug DR-01 tested for alopecia and vitiligo

NCT ID NCT06602232

Ongoing Disease control Sponsor: Dren Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This early-stage study tests a new medicine called DR-01 in 81 adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. Participants are randomly assigned to different doses, and everyone knows which treatment they receive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata disorder of pilosebaceous unit skin disorder vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA VITILIGO

Contacts and locations

Locations

  • Dren Investigational Site

    Northridge, California, 91344, United States

  • Dren Investigational Site

    Miami, Florida, 33155, United States

  • Dren Investigational Site

    Evans, Georgia, 30809, United States

  • Dren Investigational Site

    Meridian, Idaho, 83642, United States

  • Dren Investigational Site

    Indianapolis, Indiana, 46250, United States

  • Dren Investigational Site

    West Lafayette, Indiana, 47906, United States

  • Dren Investigational Site

    Worcester, Massachusetts, 01605, United States

  • Dren Investigational Site

    Troy, Michigan, 48084, United States

  • Dren Investigational Site

    Philadelphia, Pennsylvania, 19103, United States

  • Dren Investigational Site

    Pittsburgh, Pennsylvania, 15213, United States

  • Dren Investigational Site

    Chattanooga, Tennessee, 37421, United States

  • Dren Investigational Site

    San Antonio, Texas, 78215, United States

  • Dren Investigational Site

    Charlestown, New South Wales, 2290, Australia

  • Dren Investigational Site

    Darlinghurst, New South Wales, 2010, Australia

  • Dren Investigational Site

    Coorparoo, Queensland, 4151, Australia

  • Dren Investigational Site

    South Yarra, Victoria, 3141, Australia

  • Dren Investigational Site

    Fremantle, Washington, Australia

  • Dren Investigational Site

    Auckland, 0632, New Zealand

  • Dren Investigational Site

    Christchurch, 8013, New Zealand

  • Dren Investigational Site

    Grafton, 1010, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.